Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Preclinical Toxicity Evaluation of AAV for Pain: Evidence from Human AAV Studies and from the Pharmacology of Analgesic Drugs
Pleticha, Josef, Heilmann, L. , Evans, Christopher H. , Samulski, R. Jude , Beutler, Andreas S. , Asokan, Aravind

Molecular Pain | September 2, 2014 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1186/1744-8069-10-54 | PMID 25183392 Get It

Gene therapy with adeno-associated virus (AAV) has advanced in the last few years from promising results in animal models to >100 clinical trials (reported or under way). While vector availability was a substantial hurdle a decade ago, innovative new production methods now routinely match the scale of AAV doses required for clinical testing. These advances may become relevant to translational research in the chronic pain field. AAV for pain targeting the peripheral nervous system was proven to be efficacious in rodent models several years ago, but has not yet been tested in humans. The present review addresses the steps needed for translation of AAV for pain from the bench to the bedside focusing on pre-clinical toxicology. We break the potential toxicities into three conceptual categories of risk: First, risks related to the delivery procedure used to administer the vector. Second, risks related to AAV biology, i.e., effects of the vector itself that may occur independently of the transgene. Third, risks related to the effects of the therapeutic transgene. To identify potential toxicities, we consulted the existing evidence from AAV gene therapy for other nervous system disorders (animal toxicology and human studies) and from the clinical pharmacology of conventional analgesic drugs. Thereby, we identified required preclinical studies and charted a hypothetical path towards a future phase I/II clinical trial in the oncology-palliative care setting.
Exogenous Interleukin-17A Inhibits Eosinophil Differentiation and Alleviates Allergic Airway Inflammation
Tian, Baoping, Wen, Hua , Xia, Lixia, Jin, Yan, Lan, Fen , Lee, James J. , Lee, Nancy A., Ying, Songmin , Chen, Zhihua , Shen, Huahao , Li, Wen

American Journal of Respiratory Cell and Molecular Biology | September 2, 2014 | Volume: 52 | Issue: 4 | Pages: 459-470

10.1165/rcmb.2014-0097oc | PMID 25180833 Get It

Abstract IL-17 is known to play important roles in immune and inflammatory disease, such as in asthma, but its functions in allergic airway inflammation are still controversial, and the molecular mechanisms mediating these functions remain unclear. Increased production of eosinophils in bone marrow and their emergence in the airway have been linked to the onset and progression of allergic asthma. In this study, we investigated the effects of exogenous IL-17 on allergic airway inflammation and explored the underlying molecular mechanisms through eosinophil generation. Exogenous IL-17 significantly attenuated the features of allergic inflammation induced by ovalbumin in mice. It inhibited eosinophil differentiation both in vivo and in vitro, accompanied by down-regulated expression of CC chemokine receptor 3, GATA binding protein 1 (GATA-1), and GATA binding protein 2 (GATA-2), as well as reduced formation of common myeloid progenitors and eosinophil progenitors, but without influencing eosinophil apoptosis. IL-17 also significantly decreased the number of eosinophils in IL-5–transgenic mice, although it notably increased the levels of IL-3, IL-5, and granulocyte/macrophage colony–stimulating factor. In addition, IL-17 had little effect on secretion of the inflammatory cytokines by eosinophils. Neutralization of endogenous IL-17 significantly augmented eosinophil recruitment in the airways. Together, these findings suggest that exogenous IL-17 protects against allergic airway inflammation, most likely through inhibition of the eosinophil differentiation in bone marrow.
Clark T. Sawin Historical Vignette: What Do Criminology, Harry Houdini, and King George V Have in Common with Postpartum Thyroid Dysfunction?
Smallridge, Robert C.

Thyroid® | September 2, 2014 | Volume: 24 | Issue: 12 | Pages: 1752-1758

10.1089/thy.2014.0165 | PMID 25180618 Get It

The history of postpartum thyroid dysfunction (PPTD) dates back almost two millennia, when Soranus of Ephesus, who practiced obstetrics and neonatology, observed swelling in the necks (presumably goiters) of women after pregnancy. The next reference to PPTD appeared in artwork more than 1000 years later, with many portraits illustrating women with goiter while holding infants. In the early to mid-19th century, Caleb Hillier Parry and Armand Trousseau described postpartum hyperthyroidism, while in the late 1800s, Sir Horatio Bryan Donkin reported the first patient with postpartum hypothyroidism. The modern era of PPTD began with the description in the late 1940s by H.E.W. Roberton of women after delivery reporting hypothyroid symptoms and responding to thyroid extract. The immunologic influence on PPTD was recognized initially by Parker and Beierwaltes in the early 1960s, and the clinical variability and natural history were carefully documented by numerous investigators in the 1970s–1980s. The past two decades have seen further refinements in understanding the prevalence, etiology, and treatment of PPTD. Yet to be determined is the role of screening as a cost-effective measure.
Shape expressions
Prud’hommeaux, Eric , Gayo, José Emilio Labra , Solbrig, Harold R.

Proceedings of the 10th International Conference on Semantic Systems | September 2, 2014 | Volume: No volume available | Issue: No issue available | Pages: 32-40

10.1145/2660517.2660523 Get It

Spirometry in the Occupational Setting
Ruppel, Gregg L , Mottram, Carl

American Journal of Respiratory and Critical Care Medicine | September 2, 2014 | Volume: 190 | Issue: 3 | Pages: 352-353

10.1164/rccm.201405-0813le | PMID 25084266 Get It

Greatest rapid eye movement sleep atonia loss in men and older age
McCarter, Stuart J. , Louis, Erik K. St. , Sandness, David J., Silber, Michael H. , St Louis, Erik K, Boeve, Bradley F. , St Louis, E K , McCarter, Stuart J

Annals of Clinical and Translational Neurology | September 2, 2014 | Volume: 1 | Issue: 9 | Pages: 733-738

10.1002/acn3.93 | PMID 25493286 Get It

ICE Imaging of the Left Atrial Appendage
Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | September 2, 2014 | Volume: 25 | Issue: 11 | Pages: 1272-1274

10.1111/jce.12536 | PMID 25181549 Get It

National heart, lung, and blood institute state of the science symposium in therapeutic apheresis—Therapeutic apheresis in cardiovascular disease
Cooper, Leslie T. , Ratcliffe, Nora, Wu, Yanyun , Moriarty, Patrick M. , Winters, Jeffrey L. , Cooper, Leslie T

Journal of Clinical Apheresis | September 2, 2014 | Volume: 30 | Issue: 3 | Pages: 183-187

10.1002/jca.21355 | PMID 25181584 Get It

The National Heart, Lung, and Blood Institute in collaboration with the American Society for Apheresis, convened a State of the Science Symposium in November of 2012 due to the expanding application of therapeutic apheresis despite the lack of well‐designed research to address its efficacy. This article reviews the opportunities that were presented at this meeting in the area of cardiovascular disease (CVD), specifically the use of columns to adsorb autoantibodies in dilated cardiomyopathy or damaging lipids in peripheral vascular disease. Understanding how absorption of these pathologic substances alters the inflammatory response in these disorders is important for the application of these technologies to the treatment of CVD. J. Clin. Apheresis 30:183–187, 2015. © 2014 Wiley Periodicals, Inc.
Melittin Inhibits TGF-β-Induced Pro-Fibrotic Gene Expression Through the Suppression of the TGFβRII-Smad, ERK1/2 and JNK-Mediated Signaling Pathway
Park, Suhyun , Cho, Hyun-Ji , Shin, Jae-Moon, Kang, Jeong Han , Park, Kwan‐Kyu , Choe, Jung‐Yoon , Park, Yoon-Yub , Han, Sang‐Mi , Moon, Sung‐Kwon , Chang, Young‐Chae , Jeong, Yun‐Jeong , Bae, Young‐Seuk , Kim, Wun‐Jae , Choi, Yung Hyun

The American Journal of Chinese Medicine | September 2, 2014 | Volume: 42 | Issue: 05 | Pages: 1139-1152

10.1142/s0192415x14500712 | PMID 25178280 Get It

Renal fibrosis is characterized by the excessive accumulation of extracellular matrix (ECM) proteins such as type I collagen, fibronectin, and by the increased expression of PAI-1. This study evaluated the anti-fibrotic effect of bee venom and its major compounds (melittin and apamin) on TGF-β-induced pro-fibrotic gene expression. Bee venom and melittin significantly suppressed type I collagen, fibronectin, and PAI-1 protein expression in the TGF-β-treated kidney fibroblast. However, apamin only inhibited the expression of fibronectin and type I collagen. These results indicated that the inhibitory effects of bee venom on TGF-β-induced pro-fibrotic gene expression are caused by melittin. Moreover, we attempted to elucidate mechanisms underlying the anti-fibrotic effect of melittin. Melittin dramatically inhibited the phosphorylation of TGFβRII and Smad2/3. Also, melittin inhibited the phosphorylation of ERK1/2 and JNK, but not the phosphorylation of PI3K, Akt, and p38. These results suggested that melittin inhibits TGF-β-induced pro-fibrotic genes expression through the suppression of TGFβR-Smad2/3, ERK1/2, and JNK phosphorylation, and melittin can be used as a clinical drug for the treatment of fibrosis associated with renal diseases.